The shifting UK environment surrounding entheogens is increasingly intricate, demanding careful navigation. While therapeutic investigation into compounds like psilocybin and copyright continues to unfold, and patient opportunity via private clinics is expanding, the regulatory framework remains unclear. This presents a challenging situation for bo